



15th January 2010

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 3000

Phylogica 's 2010 Technical and Investor Presentations
now available for download

Today Phylogica's Chief Scientific Officer Professor Paul Watt presented at the CHI Peptalk 2010 symposium (<http://www.chi-peptalk.com>) in San Diego.

This presentation and the current sophisticated investor presentation, are available for download from the Company website <http://www.phylogica.com/display/index/investors-presentations>

About Phylomers

Phylomer[®] peptides are derived from biodiverse natural sequences which have been selected by evolution to form stable structures which can bind tightly and specifically to disease-associated target proteins. Suitable targets for Phylomer[®] blockade include protein interactions that promote multiple disease, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer[®] peptides can have drug-like properties including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer[®] peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery. Phylogica has recently initiated a collaboration with Aegis Therapeutics LLC (www.aegisthera.com), to develop the delivery of Phylomer[®] peptides by their formulation using Intravail[®] for transmucosal delivery.

About Phylogica (www.phylogica.com)

Phylogica is a biopharmaceutical company focusing on the discovery, development and commercialization of Phylomer[®] peptides, especially for inflammatory diseases. Phylogica engages in the discovery and validation of Phylomer[®] peptides for the development of innovative therapeutic products, through relationships with commercial partners and its in-house drug discovery programmes. Phylogica's discovery platform uses its proprietary Phylomer[®] libraries, a highly diverse and complex collection of billions of Phylomer[®] peptides, to provide a rich source of potent drug leads for a broad range of disease targets. Over the past few years, Phylogica has gained significant leverage in the area of peptide drug discovery by establishing proprietary rights for their Phylomer[®] libraries and screening methods which, when combined with Phylogica's significant know-how in the field of drug discovery, constitutes a powerful drug discovery platform which offers the highest hit-rates for bioactive peptides.

Phylogica[®] and Phylomer[®] are registered service marks of the company in Australia and USA, and Phylomer[®] is also a registered goods mark of the company in Australia.

Dr Paul Watt – Director
paulw@phylogica.com

Suite 3, 257 York St, Subiaco, Western Australia 6008
Tel: (08) 9382 8888 Fax: (08) 9382 1766
PO Box 8207, Subiaco East WA 6008
www.phylogica.com

ABN 48 098 391 961